BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32887417)

  • 1. 5-Fluorouracil Conversion Pathway Mutations in Gastric Cancer.
    Biagioni A; Staderini F; Peri S; Versienti G; Schiavone N; Cianchi F; Papucci L; Magnelli L
    Biology (Basel); 2020 Sep; 9(9):. PubMed ID: 32887417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells.
    Xu ZY; Tang JN; Xie HX; Du YA; Huang L; Yu PF; Cheng XD
    Int J Biol Sci; 2015; 11(3):284-94. PubMed ID: 25678847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
    Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
    Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
    van Kuilenburg AB; De Abreu RA; van Gennip AH
    Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes.
    Saif MW; Smith M; Maloney A
    Cureus; 2016 Sep; 8(9):e783. PubMed ID: 27752409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.
    Yu B; Gu D; Zhang X; Liu B; Xie J
    J Genet Genomics; 2017 Aug; 44(8):375-383. PubMed ID: 28847472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
    Collie-Duguid ES; Etienne MC; Milano G; McLeod HL
    Pharmacogenetics; 2000 Apr; 10(3):217-23. PubMed ID: 10803677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.
    Huang H; Han Y; Zhang C; Wu J; Feng J; Qu L; Shou C
    Tumour Biol; 2016 Mar; 37(3):3527-34. PubMed ID: 26453116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy.
    van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Bakker PJ; Guchelaar HJ; Richel DJ
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):726-32. PubMed ID: 18600532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
    van Kuilenburg AB
    Cancer Invest; 2006 Mar; 24(2):215-7. PubMed ID: 16537192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK.
    Park JB; Lee JS; Lee MS; Cha EY; Kim S; Sul JY
    Mol Med Rep; 2018 Sep; 18(3):2880-2888. PubMed ID: 30015846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evolution from pharmacokinetics to pharmacogenetics. The example of 5-fluorouracil].
    Milano G; Etienne MC
    Rev Med Interne; 1994 Apr; 15(4):287-91. PubMed ID: 8059151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Chang W; Guan W; Liu Y; Shen Q; Yu Y; Zhang H; Cao G
    Cancer; 2013 Oct; 119(19):3436-45. PubMed ID: 23821160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
    Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
    Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral fluorinated pyrimidines.
    de Bono JS; Twelves CJ
    Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.